Our meta analysis showed that PD-1/PD-L1 antibodies treatment significantly improved the OS, PFS and ORR of advanced SQ- and NSQ-NSCLC patients as compared to docetaxel as second-line therapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.